Pharmacological interventions for the treatment of smokeless tobacco use / Jon O. Ebbert (2012)

Public Titre : Pharmacological interventions for the treatment of smokeless tobacco use Type de document : texte imprimé Auteurs : Jon O. Ebbert, Auteur ; Karl Fagerström, Auteur Editeur : Adis International Année de publication : 2012 Collection : CNS Drugs, ISSN 1172-7047 num. Vol. 26 Importance : 10 p. Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3 Approche pharmacologique Résumé : Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified in a recent meta-analysis of interventions for SLT users, with inclusion of additional articles identified by searching PubMed up to August 2011. Nicotine replacement therapy (NRT) has been demonstrated to increase short-term tobacco abstinence rates and to alleviate craving and withdrawal symptoms among SLT users trying to quit. Bupropion sustained release has been shown to decrease craving and attenuate post-cessation weight gain among SLT users trying to quit. Varenicline is the only available medication demonstrated to increase long-term (≥6 months) tobacco abstinence rates among SLT users. Overall, findings from studies investigating pharmacotherapies for SLT users have been relatively disappointing. SLT reduction interventions may hold some promise for increasing abstinence rates among SLT users not interested in quitting. Additional investigations of higher dose NRT and combination pharmacotherapy are needed to advance the treatment of SLT users. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7959

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 005500	TA 6.2.3 EBB P	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Varenicline / Gillian M. Keating (2006)

Public Titre : Varenicline : a review of its use as an aid to smoking cessation therapy Type de document : texte imprimé Auteurs : Gillian M. Keating, Auteur ; Asif A. Siddiqui, Auteur Editeur : Adis International Année de publication : 2006 Collection : CNS Drugs, ISSN 1172-7047 num. Vol 20, n. 11 Importance : p. 945-960 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract Varenicline is an orally administered alpha4beta2 nicotinic acetylcholine (ACh) receptor partial agonist. It has been approved by the US FDA (Chantix) and the European Commission (Champix) for use as an aid to smoking cessation therapy. Varenicline is an effective and generally well tolerated treatment for use in smokers who want to quit. In two well designed, phase III trials, 12 weeks' treatment with varenicline was associated with significantly higher continuous abstinence rates at weeks 9-12 than placebo or bupropion sustained-release (SR). In the longer term, continuous abstinence rates for weeks 9 through 52 demonstrated that the odds of remaining abstinent were 2.7 to 3.1 times higher with 12 weeks of varenicline treatment than with placebo; the significant difference between varenicline and bupropion SR was also maintained in the longer term in one trial. Moreover, varenicline appeared to attenuate the urge to smoke, negative affect withdrawal symptoms and the reinforcing effects of smoking. Among those achieving abstinence, an additional 12 weeks of varenicline therapy helped increase the likelihood of long-term abstinence. Thus, varenicline is a valuable new agent for use as an aid to smoking cessation treatment. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7942

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 005483	TA 6.2.3.1.4 KEA V	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !